CeriBell (NASDAQ:CBLL) Director William Burke Sells 2,207 Shares

CeriBell, Inc. (NASDAQ:CBLL) Director William Burke sold 2,207 shares of the company’s stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $19.84, for a total value of $43,786.88. Following the completion of the transaction, the director owned 23,022 shares in the company, valued at $456,756.48. This represents a 8.75% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

CeriBell Stock Performance

Shares of NASDAQ CBLL opened at $19.55 on Friday. The firm has a 50 day moving average of $18.81 and a 200 day moving average of $19.72. The firm has a market capitalization of $741.73 million, a price-to-earnings ratio of -11.99 and a beta of 0.77. CeriBell, Inc. has a 12-month low of $10.85 and a 12-month high of $24.33. The company has a current ratio of 10.44, a quick ratio of 10.01 and a debt-to-equity ratio of 0.14.

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.13). The company had revenue of $26.49 million during the quarter, compared to the consensus estimate of $26.09 million. CeriBell had a negative return on equity of 38.19% and a negative net margin of 63.51%. On average, research analysts anticipate that CeriBell, Inc. will post -1.69 earnings per share for the current year.

Institutional Trading of CeriBell

Hedge funds have recently modified their holdings of the company. Vanguard Group Inc. grew its holdings in shares of CeriBell by 11.1% in the third quarter. Vanguard Group Inc. now owns 1,473,856 shares of the company’s stock valued at $16,935,000 after purchasing an additional 147,013 shares in the last quarter. KCM Capital Inc grew its stake in shares of CeriBell by 40.0% in the 1st quarter. KCM Capital Inc now owns 1,400,000 shares of the company’s stock worth $25,662,000 after buying an additional 400,000 shares in the last quarter. Yu Fan increased its holdings in shares of CeriBell by 10.7% in the 2nd quarter. Yu Fan now owns 1,353,166 shares of the company’s stock worth $25,345,000 after buying an additional 130,964 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in shares of CeriBell by 1,945.9% in the 4th quarter. Bank of New York Mellon Corp now owns 1,221,927 shares of the company’s stock worth $26,797,000 after buying an additional 1,162,200 shares during the last quarter. Finally, Novo Holdings A S raised its position in shares of CeriBell by 2.3% during the 2nd quarter. Novo Holdings A S now owns 900,000 shares of the company’s stock valued at $16,857,000 after buying an additional 20,000 shares in the last quarter.

Analysts Set New Price Targets

CBLL has been the subject of several recent analyst reports. Weiss Ratings raised shares of CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday. Canaccord Genuity Group lowered their price objective on CeriBell from $28.00 to $25.00 and set a “buy” rating on the stock in a research report on Tuesday, May 12th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $22.20.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.